OCX News and Press, Oncocyte Corporation

NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leader within the financial markets and news community, announces the release of an article highlighting the precision diagnostics company, Oncocyte’s (Nasdaq: OCX) appointment of leading finance executive, Andrea Jame...

2024-06-17 16:20:34 ET More on OncoCyte OncoCyte Corporation (OCX) Q1 2024 Earnings Call Transcript Oncocyte stock rallies 90% post-market on Bio-Rad partnership Seeking Alpha’s Quant Rating on OncoCyte Historical earnings data for OncoCyte R...

IRVINE, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that it has appointed leading finance executive, Andrea James, to the position of Chief Financial Officer. “We are thrilled to welcome Andrea...

(NewsDirect) Chronic conditions such as organ transplant rejection and cancer represent significant challenges in modern healthcare, demanding precise diagnostic tools for effective management and treatment. For organ transplant patients, the risk of graft rejection remains a persistent threa...

NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Oncocyte’s (Nasdaq: OCX) VitaGraft Kidney™ diagnostic test for transplant monitoring has shown promising results in a Phase 2 clinical trial, published in the prestigious New England Journal of Medicine. The trial evaluated the test's effe...

Late-breaking presentation of data at American Transplant Congress on Monday, June 3 Data show potential to monitor for therapeutic efficacy and recurrence Potential repeat testing opportunities with claims expansion IRVINE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp...

2024-05-15 22:15:34 ET OncoCyte Corporation (OCX) Q1 2024 Earnings Conference Call May 15, 2024 16:30 ET Company Participants Jeff Ramson - Investor Relations Josh Riggs - President and Chief Executive Officer Conference Call Participants Mike Matson - Ne...

2024-05-15 16:27:46 ET More on OncoCyte OncoCyte Corporation (OCX) Q4 2023 Earnings Call Transcript Oncocyte stock rallies 90% post-market on Bio-Rad partnership Seeking Alpha’s Quant Rating on OncoCyte Historical earnings data for OncoCyte Fin...

IRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the quarter ended March 31, 2024. Recent Highlights Announced global commercialization partnership with Bio-Rad Labora...

Bank of Georgia Group Plc (BDGSF) is expected to report for Q1 2024 iCad Inc. (ICAD) is expected to report for Q1 2024 Yasheng Group (HERB) is expected to report for Q1 2024 Bit Digital Inc. (BTBT) is expected to report $0.01 for Q1 2024 Estrella Immunopharma Inc. (ESLA) is expect...